Diabetic Nephropathy and Extracellular Matrix
Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased...
Gespeichert in:
Veröffentlicht in: | The journal of histochemistry and cytochemistry 2012-12, Vol.60 (12), p.976-986 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 986 |
---|---|
container_issue | 12 |
container_start_page | 976 |
container_title | The journal of histochemistry and cytochemistry |
container_volume | 60 |
creator | Kolset, S. O. Reinholt, F. P. Jenssen, T. |
description | Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established. |
doi_str_mv | 10.1369/0022155412465073 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3527883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1369_0022155412465073</sage_id><sourcerecordid>1221131543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</originalsourceid><addsrcrecordid>eNp1kM1PwzAMxSMEYmNw54R25FKI89GGCxIa40MacIFz5KbJ1qlrS9Ki7b-n1QYCJE6W9Z6f7R8hp0AvgMdXl5QyBlIKYCKWNOF7ZNi1EEkqxD4Z9nLU6wNyFMKSUhBCqkMyYBwoTxgfkug2x9Q2uRk_23rhqxqbxWaMZTaerhuPxhZFW6AfP2Hj8_UxOXBYBHuyqyPydjd9nTxEs5f7x8nNLDKS0iaCFISNeewUmow7oOiEoooZB1xyQJupJGOGOUhSJhkmBlCgktxZzpEJPiLX29y6TVc2M7bsbil07fMV-o2uMNe_lTJf6Hn1oblkiVK8CzjfBfjqvbWh0as89M9gaas2aOi4AQcpeivdWo2vQvDWfa8BqnvK-i_lbuTs53nfA19YO0O0NQScW72sWl92uP4P_AQnfoP9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221131543</pqid></control><display><type>article</type><title>Diabetic Nephropathy and Extracellular Matrix</title><source>Access via SAGE</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Kolset, S. O. ; Reinholt, F. P. ; Jenssen, T.</creator><creatorcontrib>Kolset, S. O. ; Reinholt, F. P. ; Jenssen, T.</creatorcontrib><description>Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.</description><identifier>ISSN: 0022-1554</identifier><identifier>EISSN: 1551-5044</identifier><identifier>DOI: 10.1369/0022155412465073</identifier><identifier>PMID: 23103723</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Animals ; Chondroitin Sulfates - metabolism ; Dermatan Sulfate - metabolism ; Diabetic Neuropathies - metabolism ; Diabetic Neuropathies - physiopathology ; Diabetic Neuropathies - therapy ; Extracellular Matrix - metabolism ; Glycocalyx - pathology ; Heparan Sulfate Proteoglycans - metabolism ; Humans ; Kidney - metabolism ; Kidney - pathology ; Kidney - physiopathology ; Matrix Metalloproteinases - metabolism ; Proteoglycans - metabolism ; Signal Transduction</subject><ispartof>The journal of histochemistry and cytochemistry, 2012-12, Vol.60 (12), p.976-986</ispartof><rights>The Author(s) 2012</rights><rights>The Author(s) 2012 2012 The Histochemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</citedby><cites>FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1369/0022155412465073$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1369/0022155412465073$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>230,314,780,784,885,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23103723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kolset, S. O.</creatorcontrib><creatorcontrib>Reinholt, F. P.</creatorcontrib><creatorcontrib>Jenssen, T.</creatorcontrib><title>Diabetic Nephropathy and Extracellular Matrix</title><title>The journal of histochemistry and cytochemistry</title><addtitle>J Histochem Cytochem</addtitle><description>Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.</description><subject>Animals</subject><subject>Chondroitin Sulfates - metabolism</subject><subject>Dermatan Sulfate - metabolism</subject><subject>Diabetic Neuropathies - metabolism</subject><subject>Diabetic Neuropathies - physiopathology</subject><subject>Diabetic Neuropathies - therapy</subject><subject>Extracellular Matrix - metabolism</subject><subject>Glycocalyx - pathology</subject><subject>Heparan Sulfate Proteoglycans - metabolism</subject><subject>Humans</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Kidney - physiopathology</subject><subject>Matrix Metalloproteinases - metabolism</subject><subject>Proteoglycans - metabolism</subject><subject>Signal Transduction</subject><issn>0022-1554</issn><issn>1551-5044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1PwzAMxSMEYmNw54R25FKI89GGCxIa40MacIFz5KbJ1qlrS9Ki7b-n1QYCJE6W9Z6f7R8hp0AvgMdXl5QyBlIKYCKWNOF7ZNi1EEkqxD4Z9nLU6wNyFMKSUhBCqkMyYBwoTxgfkug2x9Q2uRk_23rhqxqbxWaMZTaerhuPxhZFW6AfP2Hj8_UxOXBYBHuyqyPydjd9nTxEs5f7x8nNLDKS0iaCFISNeewUmow7oOiEoooZB1xyQJupJGOGOUhSJhkmBlCgktxZzpEJPiLX29y6TVc2M7bsbil07fMV-o2uMNe_lTJf6Hn1oblkiVK8CzjfBfjqvbWh0as89M9gaas2aOi4AQcpeivdWo2vQvDWfa8BqnvK-i_lbuTs53nfA19YO0O0NQScW72sWl92uP4P_AQnfoP9</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Kolset, S. O.</creator><creator>Reinholt, F. P.</creator><creator>Jenssen, T.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121201</creationdate><title>Diabetic Nephropathy and Extracellular Matrix</title><author>Kolset, S. O. ; Reinholt, F. P. ; Jenssen, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Chondroitin Sulfates - metabolism</topic><topic>Dermatan Sulfate - metabolism</topic><topic>Diabetic Neuropathies - metabolism</topic><topic>Diabetic Neuropathies - physiopathology</topic><topic>Diabetic Neuropathies - therapy</topic><topic>Extracellular Matrix - metabolism</topic><topic>Glycocalyx - pathology</topic><topic>Heparan Sulfate Proteoglycans - metabolism</topic><topic>Humans</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Kidney - physiopathology</topic><topic>Matrix Metalloproteinases - metabolism</topic><topic>Proteoglycans - metabolism</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kolset, S. O.</creatorcontrib><creatorcontrib>Reinholt, F. P.</creatorcontrib><creatorcontrib>Jenssen, T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of histochemistry and cytochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolset, S. O.</au><au>Reinholt, F. P.</au><au>Jenssen, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diabetic Nephropathy and Extracellular Matrix</atitle><jtitle>The journal of histochemistry and cytochemistry</jtitle><addtitle>J Histochem Cytochem</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>60</volume><issue>12</issue><spage>976</spage><epage>986</epage><pages>976-986</pages><issn>0022-1554</issn><eissn>1551-5044</eissn><abstract>Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>23103723</pmid><doi>10.1369/0022155412465073</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1554 |
ispartof | The journal of histochemistry and cytochemistry, 2012-12, Vol.60 (12), p.976-986 |
issn | 0022-1554 1551-5044 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3527883 |
source | Access via SAGE; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
subjects | Animals Chondroitin Sulfates - metabolism Dermatan Sulfate - metabolism Diabetic Neuropathies - metabolism Diabetic Neuropathies - physiopathology Diabetic Neuropathies - therapy Extracellular Matrix - metabolism Glycocalyx - pathology Heparan Sulfate Proteoglycans - metabolism Humans Kidney - metabolism Kidney - pathology Kidney - physiopathology Matrix Metalloproteinases - metabolism Proteoglycans - metabolism Signal Transduction |
title | Diabetic Nephropathy and Extracellular Matrix |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A25%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diabetic%20Nephropathy%20and%20Extracellular%20Matrix&rft.jtitle=The%20journal%20of%20histochemistry%20and%20cytochemistry&rft.au=Kolset,%20S.%20O.&rft.date=2012-12-01&rft.volume=60&rft.issue=12&rft.spage=976&rft.epage=986&rft.pages=976-986&rft.issn=0022-1554&rft.eissn=1551-5044&rft_id=info:doi/10.1369/0022155412465073&rft_dat=%3Cproquest_pubme%3E1221131543%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221131543&rft_id=info:pmid/23103723&rft_sage_id=10.1369_0022155412465073&rfr_iscdi=true |